Purpose of review The goal of this review is to review the current status of prokinetics and to place it in historical context. Impaired motility and thus propulsion have long been thought to play important roles in the pathogenesis of a number of gastrointestinal disorders including gastroesophageal reflux disease (GERD), gastroparesis, chronic idiopathic pseudo-obstruction, and constipation. Historically, disordered motility was also thought to contribute to a number of functional gastrointestinal disorders such as functional dyspepsia (FD) and irritable bowel syndrome (IBS). Recent findings As we learn more of the pathophysiology of FD, IBS, GERD, constipation, and gastroparesis, the limitations of a therapeutic strategy based on the stimulation of motility (i.e., the use of a prokinetic) have become apparent and the disappointments of the past explained. The development of prokinetic drugs has also been hampered by the nonselective nature of many of the agents studied to date which resulted in some unexpected side effects. Summary There is still an unmet need for an effective and safe prokinetic, but drug development in this area must be mindful of the challenges of the area and the need for selectivity for a given target receptor.
Introduction
Strictly speaking, the term prokinetic should be restricted to pharmacological compounds that stimulate gastrointestinal smooth muscle and, thereby, it is assumed, accelerated transit. This property may be readily demonstrable in an organ bath but, given the complexity of the organization and modulation of motility in the intact gut, may be an overly simplistic concept in clinical practice. Even in disorders such as gastroesophageal reflux, gastroparesis, intestinal pseudo-obstruction, and colonic inertia where the stimulation of motility might be considered a worthwhile goal, we now realize that other factors are involved which might or might not respond to a prokinetic. When one moves to functional disorders, such as functional dyspepsia and irritable bowel syndrome where dysmotility was once thought to play a major role and prokinetics, therefore, prescribed, the challenge becomes even more daunting. Here, one is confronted, not only by the intrinsic heterogeneity of these disorders but also by the variable contributions of such factors as disordered brain processing of visceral signals, psychopathology, visceral hypersensitivity, changes in gut compliance and accommodation, immune activation, and an altered microbiome to their pathophysiology. As our understanding of the various levels of control of gut muscle and their interactivity came to be appreciated, the challenges that lay ahead for those who sought new therapies for disorders thought to be based on dysmotility began to be appreciated. In attempting to understand the various disorders encompassed within the relatively new discipline of neurogastroenterology, hypomotility has been relegated to a minor role and concepts such as enteric neuromodulation rather than prokinesia have emerged. Drug development has lagged behind, however, and most of the agents that we have (or had) at our disposal were developed as prokinetics. Needless to say, pharmacological and other approaches targeted at the various phenomena that may be relevant to the basic pathogenesis or symptom generation in this field are being explored; space does not permit a complete discussion of such endeavors, and the reader is instead referred to an elegant review by Camilleri [1] . Here, we will concentrate on drugs that were developed as prokinetics in the original definition of the term.
The Prokinetic Approach: Challenges
Decades of false dawns, therapeutic disappointment, and even drug withdrawals have highlighted in bold the challenges inherent to the introduction of a drug designed to stimulate gastrointestinal motility into clinical practice. The following issues have proven especially problematic.
Is the Very Concept of a Prokinetic Misplaced?
If one assumes that a number of clinical disorders are based on absent or impaired motility, then an approach that sets out to stimulate motility via the augmentation or mimicking of the major excitatory neurotransmitters of the gastrointestinal tract (such as acetylcholine) makes sense. But is this the case or is the story a bit more complicated? [2] . The fraught history of our attempts to define, diagnose, and treat gastroparesis vividly illustrates the naiveté of the prokinetic approach. Based on the assumption that gastric hypomotility led to delayed emptying and thus to symptoms, gastroparesis served as the testing ground for various prokinetics. It was here also that they withered and died. Why? It is now evident that the symptoms of gastroparesis, the clinical syndrome, owe their origin to many factors other than the one we can most readily measure, gastric emptying: impaired accommodation, visceral hypersensitivity, and antral distension, to mention but a few [3•] . Along similar lines, it is equally obvious that attributing all instances of chronic idiopathic constipation to colonic inertia was another oversimplification of a clinical problem that is now seen to involve, among others, more complex alterations in colonic motor function [4, 5•] , defecatory and pelvic floor dysfunction [6] , rectal hyposensitivity [7] , and colonic secretion [8] . From this perspective, the limitations of an exclusively prokinetic approach seem obvious [9••] .
The Hazard of Using Prokinetics to Treat Disorders that Are Poorly Defined
Some motility disorders, such as achalasia, scleroderma, or Hirschsprung's disease, are well defined in terms of pathology, pathophysiology, and clinical recognition and form the basis for logical approaches to therapy. These are relatively rare, however, and unlikely to catch the eye of a pharmaceutical company developing a new compound that stimulates gut motility. Much more common are the so-called functional gastrointestinal disorders (FGIDs) which encompass large segments of the population and hold great promise for returns on new compounds. For what seemed to be good reasons at the time, FGIDs such as functional dyspepsia, irritable bowel syndrome, and chronic idiopathic constipation came to be regarded as "motility disorders" and accordingly targets for novel prokinetics. The definition of these disorders relies exclusively on symptoms and the exclusion of "organic" disorders; an unsatisfactory situation which no doubt contributed to the undoubted heterogeneity of their included patient populations and pathophysiology [10] and rendered it highly unlikely that a therapeutic approach based on a single mechanism (such as prokinesia) would help all patients. FGIDs have not been fertile grounds for blockbuster drugs.
The Perils of Non-Selectivity
One lesson that emerges in vivid color from a perusal of the history of drugs targeted at a certain receptor is that selectivity is critical in predicting not only efficacy but also safety. Nonselectivity results in unpredictable and potentially conflicting effects on the gastrointestinal tract and increases the likelihood of adverse outcomes. While non-selectivity led to poorly tolerated bladder spasms with bethanechol, it led to some fatal and unanticipated outcomes with cisapride. Here, the interaction of this serotonergic agonist with the Human Ether-a-gogo-Related Gene (hERG) channel led to the occurrence of hERG channel-mediated cardiac arrhythmias, such as Torsades de Pointes and ventricular tachycardia [11] and led to its withdrawal. Valuable lessons were learned from this experience, and it is now standard practice to screen all drugs for their effects on the Q-T interval [12] . This coupled with a much greater awareness of the potential for existing drugs to interact and potentiate Q-T interval prolongation should, hopefully, prevent the development of such arrhythmias in the future. Not all drug-related cardiac events as well understood or as predictable: tegaserod, a more selective 5-hydroxytryptamine (5-HT 4 ) receptor agonist, was also withdrawn worldwide following the occurrence of a small number of largely unexplained cardiovascular events that seemed to be related to the drug [12] . Receptor and tissue selectivity are now basic goals of drug development [13] .
Paradoxically, a "dirty" drug may have some advantages in the treatment of functional disorders where pathophysiology is poorly understood and may be multifactorial. For example, cisapride possessed not just 5-HT 4 agonist activity but also acted as a 5-HT 1 agonist, an effect that enhanced fundic accommodation and reduced meal-related symptoms in functional dyspepsia [14, 15] .
Regulation-No Tolerance for Adverse Events
Having approved and then had to withdraw drugs such as cisapride and tegaserod authorities such as the Food and Drugs Administration (FDA) in the USA developed a very conservative and risk-averse approach to the evaluation and regulation of new compounds developed for motility and functional disorders. Given that these disorders were not fatal, this and other regulatory agencies instituted a "zero tolerance" approach to the occurrence of any serious drug-related occurrences in this field, a stance that has discouraged and impeded drug development and ignored the substantial impairments in quality life associated with these disorders [16] .
Available Compounds Cholinergic Agonists
Given the ubiquity of acetylcholine as a stimulatory neurotransmitter in the gastrointestinal tract, it should come as no surprise that the first prokinetic agents, such as those like bethanechol that activated the M 2 muscarinic receptor on gut myocytes, were cholinergic agonists. Lack of selectivity undoubtedly contributed to unimpressive efficacy [17] and the aforementioned adverse events and led to their replacement by more selective compounds.
Acetylcholinesterase inhibitors such as neostigmine and pyridostigmine provide alternatives to direct cholinergic agonists. Originally introduced for the treatment of Ogilvie's syndrome [18] [19] [20] [21] [22] , neostigmine has since been successfully used in the management of ileus [23] and, in exceptional circumstances, severe constipation [24] [25] [26] . The latter effects appear to be mediated by increased contractility, accelerated transit [27] , and enhanced colonic tone [28•] . The aforementioned studies involved the parenteral use of neostigmine; bradycardia was the major adverse event [28•] leading to the recommendation, by many centers, that cardiac monitoring be employed during its use. Pyridostigmine, an orally administered and longer acting acetylcholinesterase inhibitor, has also been evaluated in constipation [29, 30] . Based on the hypothesis that those with autonomic neuropathy would be more sensitive to this approach, Bharucha and colleagues demonstrated that pyridostigmine, in an escalating dose schedule, accelerated colon transit and ameliorated constipation symptoms in a group of patients with diabetes and constipation [31•].
Acetylcholinesterase inhibitors, not surprisingly, also stimulate foregut motility [30] ; this observation, together with an absence of alternatives, has led to their use, on an anecdotal basis, in gastroparesis [32••].
Acotiomide facilitates acetylcholine release from cholinergic nerve terminals by blocking M1 and M2 autoreceptors which regulate the release of acetylcholine [33] . This translated into a stimulation of gastric motility and promotion of gastric accommodation in animal studies without any apparent effect on the Q-T interval [34] . In man, while effects on gastric emptying have been less consistent [35] [36] [37] , the promotion of gastric accommodation [35, 37] led to successful clinical trials in functional dyspepsia without the emergence of any signals to suggest cardiac toxicity [35, [37] [38] [39] [40] [41] . Acotiomide has also been shown to reduce the frequency of transient lower esophageal sphincter relaxations [42] ; an impact on gastroesophageal reflux has yet to be demonstrated [43] . While acotiomide has been approved for use in a number of countries, it has not been approved in the USA.
Dopamine Antagonists
Metoclopramide is the prototypical dopamine antagonist and acts on dopamine receptors in the periphery (where it exerts its positive prokinetic effects) and in the central nervous system (conferring benefits in terms of its anti-emetic effects on the chemoreceptor trigger zone but exposing the patient to extrapyramidal side effects). In many parts of the world, but not the USA, domperidone, also a dopamine (DA 2 ) antagonist, is available and offers the potential advantage of not crossing the blood-brain barrier and, therefore, protecting (at least in theory) against CNS side effects [44, 45].
Reflecting the standards for clinical trials of the era in which it was evaluated and also all of the aforementioned problems inherent to relatively non-selective drugs in incompletely defined disorders, the clinical data base in support of metoclopramide is rather thin. Furthermore, its use in the medium to long term has been associated with the development of tolerance. Much more problematic has been an increasing concern related to the CNS adverse events [46] , experienced by as many as 25% of all exposed individuals [47] . Of the various extrapyramidal reactions linked to metoclopramide use, tardive dyskinesia may not be reversible [48] and led to the inclusion of a "black box" warning in the metoclopramide package insert in the USA and a dramatic decline in the use of this drug for gastroparesis [49] . The FDA warning states that "your chances for getting tardive dyskinesia go up the longer you take Reglan and the more Reglan you take. . This ultimately resulted in the publication of the equivalent of a black box warning by Health Canada [68] , a strategy that has not entirely eliminated risky practices such as to co-prescription of drugs that increase the cardiac toxicity of domperidone [68, 69] . The electrophysiological basis of these effects is unclear with some studies identifying arrhythmogenic effects, including Q-T interval prolongation [70, 71] , while others failed to note any such prolongation even at high doses among a group of normal volunteers [72] . Both metoclopramide and domperidone may cause galactorrhea, a side effect that was turned into a therapeutic strategy at one time but has now been curtailed because of perceived risk [73] . So what is the current verdict of domperidone? The title of the paper by Hondeghem nicely summarizes the opinion of many "Domperidone: limited benefits with significant risk for sudden cardiac death" [62] .
Levosulpiride, another but, as yet, not clinically available DA 2 antagonist accelerates gastric emptying and has been shown to improve glycemic control over a 6-month period in subjects with diabetic gastroparesis [74] . Levosulpiride also appeared effective in functional dyspepsia [75] [76] [77] [78] and especially among those with what used to be called "motility-type" dyspepsia [77, 78] , based, perhaps, on an acceleration of gastric emptying [76] . There have been no major clinical trials of this agent over the past 10 years; reports of extrapyramidal [79] [80] [81] [82] [83] and cardiac [84] side effects seemed to have dimmed enthusiasm.
Itopride is also a dopamine D2 antagonist but does not seem to induce either central nervous system or cardiovascular side effects or elevate levels of prolactin in serum to those that have resulted in mastalgia or galactorrhea with metoclopramide and domperidone [85] . Interestingly, though a meta-analysis concluded that it has positive effects in functional dyspepsia [86] , the pivotal phase III studies were resoundingly negative [87] . The latter result contrasted sharply with the positive outcome of a prior phase II study [88] ; a careful assessment of the respective study populations indicated that the positive result in the phase II study could be attributed to the more liberal inclusion of gastroesophageal reflux patients [87] , a reminder of the impact of patient selection on trial outcome in functional disorders.
Serotonergic Agonists
Cisapride, a substituted benzamide, was a highly successful prokinetic when first introduced and enjoyed widespread popularity worldwide. Its mode of action was to facilitate acetylcholine release from myenteric neurons through a 5-HT 4 receptor-mediated effect. In man, positive prokinetic effects were demonstrated in the esophagus and stomach and led to some (but not universally) positive clinical trials in gastroesophageal reflux disease, gastroparesis, and dyspepsia [89, 90] . Once reports of serious and, at times, fatal cardiac arrhythmias emerged [91, 92] , its demise was inevitable.
Search for more selective serotonergic agonists led to the introduction of an aminoguanidine indole, tegaserod. Like cisapride, it exerted clinically relevant effects on intestinal [93] , esophageal [94] , and gastric physiology [95] . It was ultimately introduced into clinical practice in the USA and some other nations for use in constipation and constipationpredominant IBS, an approval that proved short-lived due to the appearance of a small number of cardiac and vascular events that appeared to be linked to its use [96] .
While these experiences with cisapride and tegaserod cast a dark cloud over serotonergic agonists and seemed to halt development in this area, some new compounds have emerged of late. Among these, prucalopride, a benzofuran, has been approved for the treatment of refractory constipation in several countries, if not, as yet, in the USA. Prucalopride has been shown to be a high affinity, highly selective 5-HT 4 agonist that has very low affinity for other 5-HT receptors and for the hERG-K + cardiac channels [13, 97, 98] , resulting in greater efficacy and absence of arrhythmogenicity [99] . Prucalopride stimulates gastrointestinal and colonic motility, reduces esophageal acid exposure, and accelerates gastric emptying [100] [101] [102] . While the clinical focus in relation to prucalopride has been on constipation, studies on foregut disorders are awaited with interest. The observation that prucalopride exerts neuroprotective effects on human enteric neurons [103• ] could lead to its use in neuropathic disorders of the gastrointestinal tract.
Prucalopride has been studied, to date, in seven randomized placebo-controlled trials [104] [105] [106] [107] [108] [109] [110] . With one exception [110] , these demonstrated improvements in bowel function and patient satisfaction, reductions in constipation-related symptoms, and amelioration of constipation-related impairments in quality of life in adult males [109] and females [104] [105] [106] , as well as Asians and non-Asians [111•] with chronic idiopathic constipation. No benefits were seen in children [108] or in a longer term 24-week study [110] . However, prucalopride was effective among those who had failed laxatives [112] . In these pivotal trials, the most frequently encountered side effects were headache, nausea, abdominal pain or cramps, and diarrhea, all being more common than experienced by those randomized to placebo [112] .
Velusetrag is a selective 5-HT 4 agonist shown to stimulate colonic motility and transit [113] and increase the frequency of spontaneous bowel movements in sufferers with chronic constipation [114] .
In one randomized controlled trial, naronapride, another 5-HT 4 agonist, was effective in chronic constipation [115] .
As with prucalopride, these highly selective 5-HT 4 agonists have been well tolerated with the most frequent, attributable side effect being headache [116•] .
Other 5-HT 4 agonists focused on foregut disorders. Of these, revexepride failed to show efficacy in gastroparesis [117] or among gastroesophageal reflux patients who had failed proton pump inhibitor therapy [118, 119] .
Mosapride, a benzamide derivative and selective 5-HT 4 agonist [120] , accelerates gastric emptying [121] and enhances gastric accommodation [122] . Though the largest study to date showed no benefit [123] , this drug is available in a number of Asian countries for use in functional dyspepsia (FD) based, perhaps, on other studies of lower quality [124] [125] [126] [127] . Small, open-label studies have demonstrated limited efficacy of mosapride in patients with diabetic gastropathy [121, 128] and in constipation related to Parkinson's disease [129] . There is also some evidence to suggest efficacy in gastroesophageal reflux disease [130] . In contrast to cisapride, mosapride does not appear to have any significant effect on K+ channels and, accordingly, has been free of significant cardiovascular effects.
Other 5-HT 4 agonists, such as relenopride (YKP-10811) and DA-6886, are in various stages of development [131] [132] [133] .
Macrolides
Erythromycin, the prototype for this group of compounds, was shown some time ago to act as a motilin agonist. In the acute setting, intravenous erythromycin lactobionate is effective in the treatment of gastroparesis in a dose of 3 mg/kg administered every 8 h [134] . Though effective in the shortterm (5-7 days), experience with the longer term use of oral erythromycin, though limited [135] , has not been encouraging [136, 137] and, of course, exposes the patient to the risks of long-term antibiotic use [138] . Furthermore, hyperglycemia may blunt the prokinetic effect of erythromycin [138, 139] , a major limiting factor in poorly controlled diabetics. Other modes of administration are under evaluation [140, 141] . Azithromycin, a related antibiotic, exhibits better oral biovailability, accelerates gastric emptying [142] , and stimulates small intestinal motility [143] .
The search for a non-antibiotic but prokinetic macrolide [144] has so far led to the development of camicinal (GSK962040). This molecule appears to be highly selective for the motilin receptor [145] and has been shown to accelerate gastric emptying and improve nutrient delivery in both health human volunteers and patients in intensive care [146, 147•] .
Ghrelin Agonists
Another class of compounds that have been shown to have prokinetic effects are the ghrelin agonists ulimorelin (TZP-101), TZP-102, and relamorelin (RM-131) [148] . Though originally explored for their potential role in satiety, it became clear that these molecules could accelerate gastric emptying and promote colonic motor activity and transit [149-151••] . To date, ulimorelin has shown promise in the management of diabetic gastroparesis [149, 152, 153] and post-operative ileus [154] [155] [156] . TZP-102 also showed promise in gastroparesis [157] , but this was not fulfilled in a subsequent phase 2b study [158] . Of the three molecules, relamorelin looks most promising at this stage [148, 151••] and has been shown to exert positive effects on gastric [159] and colonic [160] motor function in man. These effects have translated into clinical benefits in both diabetic gastroparesis [161-163•] and chronic constipation [164•] . These compounds have to be administered parenterally, and vascular and neuroendocrine/metabolic effects need to be accounted for [165, 166] .
Conclusions
The experiences of the past decades have exposed the limitations and the dangers inherent to the prokinetic concept. There may well be an, albeit limited role, for a drug that stimulates, directly or indirectly, gut smooth muscle to accelerate transit, but most disorders for which these compounds were intended are now seen to demand a much more nuanced approach. Yes, some among those who currently carry the label gastroparesis or chronic idiopathic constipation may benefit for the stimulation of their gastric or colonic motility, but many may not and may require vastly different and even contrasting approaches. Progress has been made in understanding the many factors that contribute to common functional syndromes, and lessons have been learned (oftentimes the hard way) on the importance of identifying the optimal targets, be it population, pathophysiologic mechanism, organ, or receptor. We can only hope that from all of these experiences, new, safe, and effective prokinetics and enteric neuromodulatory drugs will emerge.
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